LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study

This Phase 1, single-center, open-label, randomized, parallel-group study will evaluate the effect of itraconazole on the PK of LTG-321 and its metabolite(s), and the safety and tolerability of LTG-321 administered alone and in combination with itraconazole, in healthy participants.

Inclusion Criteria: * Healthy adults aged 18-55 years, inclusive. * Body mass index (BMI) of 18.0-28.0 kg/m², inclusive. * Willing to meet applicable contraception and reproductive restrictions during the study and for 90 days after the last study drug dose. * Able to provide written informed consent and comply with study visits, procedures, and restrictions Exclusion Criteria: * Clinically significant medical conditions or abnormalities on examination, laboratory testing, vital signs, or ECG that could affect participant safety or study results. * Gastrointestinal conditions that could affect drug absorption, or a history of gallstones or gallbladder removal. * Pregnancy or breastfeeding. * Relevant drug allergies or contraindications to LTG-321, itraconazole, or their ingredients. * Recent smoking, vaping, or nicotine use; relevant substance or alcohol dependence history; or positive substance screening outside protocol-permitted exceptions. * Use of prohibited medications, supplements, or vaccinations within protocol-specified periods. * Known or confirmed hepatitis B, hepatitis C, or HIV infection, subject to protocol-defined exceptions. * Previous participation in an LTG-321 study, recent participation in another investigational study, or recent blood or plasma donation within prohibited periods.